Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders | Business Wire
Small Clinical Trials Lead To Big Results
Proper Résumés - Résumés that stand out and breakthrough applicant tracking systems. | Facebook
Sage advice: psychiatric drug development is tough | Evaluate
Zuranolone, a breakthrough postpartum depression treatment, was just approved by the FDA. The fast-acting pill can improve symptoms in 3 days
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
FDA Provides Expedited Path Forward For Sage's Depression Treatment SAGE-217 | BioSpace
Sage Announces Results of FDA Breakthrough Therapy Meeting – ISPE Boston
Sage Therapeutics Looks to File NDA for Postpartum Depression Treatment Later This Year | BioSpace
sage-10k_20191231.htm
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Sage advice: psychiatric drug development is tough | Evaluate
Zuranolone: Treatment Of Major Depression (MDD) And Postpartum Depression (PDD)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Biogen signs $1.5bn depression drug deal with Sage Therapeutics
Sage surges after depression drug gets rapid path to approval - PMLiVE
Rx Product News: April 2023
Sage Therapeutics surges 70% after depression drug breakthrough
Zulresso: the world's first post-partum depression drug - Pharmaceutical Technology
